Mary Wilson
New member
19 OCTOBER 2020
Christian Gaebler & Michel C. Nussenzweig
Leading COVID-19 vaccine candidates have progressed through laboratory tests at record speed. Two early clinical trials suggest that immunization delivers a favourable immune response and safety profile, but questions remain.
The catastrophic global health and socioeconomic impact of COVID-19, together with the absence of any clearly effective preventive or therapeutic remedies, has created a massive unmet medical need. Rapid responses by governments, academia and industry have already resulted in the production of more than 180 vaccine candidates[SUP]1[/SUP], 42 of which are being tested in humans at the time of writing. The considerable design flexibility of newer types of vaccine technology gave these candidates a head start in the race. Some of the candidates, which are based on nucleic acids (such as messenger RNA), entered human trials[SUP]2[/SUP] as early as March. In this issue, Mulligan et al.[SUP]3[/SUP] and Sahin et al.[SUP]4[/SUP] report clinical-trial results for a COVID-19 vaccine called BNT162b1, which contains mRNA that encodes part of a protein found on the surface of the SARS-CoV-2 coronavirus.
https://www.nature.com/articles/d41...=organic&utm_campaign=NGMT_USG_JC01_GL_Nature
Christian Gaebler & Michel C. Nussenzweig
Leading COVID-19 vaccine candidates have progressed through laboratory tests at record speed. Two early clinical trials suggest that immunization delivers a favourable immune response and safety profile, but questions remain.
The catastrophic global health and socioeconomic impact of COVID-19, together with the absence of any clearly effective preventive or therapeutic remedies, has created a massive unmet medical need. Rapid responses by governments, academia and industry have already resulted in the production of more than 180 vaccine candidates[SUP]1[/SUP], 42 of which are being tested in humans at the time of writing. The considerable design flexibility of newer types of vaccine technology gave these candidates a head start in the race. Some of the candidates, which are based on nucleic acids (such as messenger RNA), entered human trials[SUP]2[/SUP] as early as March. In this issue, Mulligan et al.[SUP]3[/SUP] and Sahin et al.[SUP]4[/SUP] report clinical-trial results for a COVID-19 vaccine called BNT162b1, which contains mRNA that encodes part of a protein found on the surface of the SARS-CoV-2 coronavirus.
https://www.nature.com/articles/d41...=organic&utm_campaign=NGMT_USG_JC01_GL_Nature